{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:01:13Z","timestamp":1783576873394,"version":"3.55.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014554","name":"Janssen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014554","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Corticosteroid (steroid) medications are associated with challenging adverse effects that can negatively impact patient quality of life. However, owing to a long legacy of effective use in treatment protocols, they remain a cornerstone of multiple myeloma (MM) care. We conducted a roundtable with Canadian healthcare providers (HCPs) with diverse healthcare backgrounds and involvement in MM care as well as with patients with MM. Our goal was to develop clear guidance for steroid management aimed at improving patient quality of life, taking into account patient perspective and experiences with managing the disease. Our recommendations, which are based on the insights acquired from this discussion, can be categorized to the following areas: steroid prescribing, dosing, and modifications; managing adverse effects; and patient-HCP communication. These recommendations can be used by the entire multi-disciplinary hematology team to improve patient quality of life while being treated with steroid medication for multiple myeloma.<\/jats:p>","DOI":"10.3389\/fonc.2022.1061417","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T05:45:07Z","timestamp":1670478307000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Canadian perspectives in multiple myeloma on the use of steroids in clinical practice based on patient and healthcare provider interviews"],"prefix":"10.3389","volume":"12","author":[{"given":"Farah","family":"McKenzie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Gazz\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Kolm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Crosbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.208.9.1680","article-title":"Treatment for multiple myeloma. combination chemotherapy with different melphalan dose regimens","volume":"208","author":"Alexanian","year":"1969","journal-title":"Jama"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08534.x","article-title":"Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma","volume":"152","author":"Ghosh","year":"2011","journal-title":"Br J Haematol"},{"key":"B3","doi-asserted-by":"publisher","first-page":":1-28","DOI":"10.1136\/jitc-2020-000734","article-title":"The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of multiple myeloma","volume":"8","author":"Shah","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00277-018-3465-8","article-title":"Glucocorticoids in multiple myeloma: Past, present, and future","volume":"98","author":"Burwick","year":"2019","journal-title":"Ann Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2022.2136950","article-title":"From mechanism to resistance - changes in the use of dexamethasone in the treatment of multiple myeloma","volume":"28","author":"Rosenberg","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1188\/08.CJON.S1.53-62","article-title":"Steroid-associated side effects in patients with multiple myeloma: Consensus statement of the imf nurse leadership board","volume":"12","author":"Faiman","year":"2008","journal-title":"Clin J Oncol Nurs"},{"key":"B7","volume-title":"Corticosteroid adverse effects. statpearls","author":"Yasir","year":"2022"},{"key":"B8","volume-title":"Product monograph: \u201cPrAPO- lenalidomide\u201d","year":"2021"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17946","article-title":"The future of myeloma research in Canada and beyond: Results of a James Lind alliance priority setting partnership","volume":"196","author":"Fowler","year":"2022","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009507","article-title":"Dose\/Schedule-adjusted Rd-r vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma","volume":"137","author":"Larocca","year":"2021","journal-title":"Blood"},{"key":"B12","unstructured":"Steroid sparing treatment with in newly diagnosed transplant ineligible patients with multiple myeloma"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O\u2019Donnell","year":"2018","journal-title":"Br J Haematol"},{"key":"B14","unstructured":"Myeloma Canada: National charitable organization2022"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1061417\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T05:45:12Z","timestamp":1670478312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1061417\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,8]]},"references-count":14,"alternative-id":["10.3389\/fonc.2022.1061417"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1061417","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,8]]},"article-number":"1061417"}}